Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 2/20 | 0.61 |
| ▸ | LATS1 | O95835 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KDM5A | P29375 | 1/20 | 0.42 |
| ▸ | NCF1 | P14598 | 2/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.41 |
| ▸ | FEN1 | P39748 | 1/20 | 0.41 |
| ▸ | PRKCB | P05771 | 1/20 | 0.40 |
| ▸ | PRKCA | P17252 | 1/20 | 0.40 |
| ▸ | PRKCH | P24723 | 1/20 | 0.40 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.40 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.40 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.40 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4751829 | 0.89 | KDR (0.58) | KDRLATS1KDM5ANCF1ADRB2 | |
| SCHEMBL31521684 | 0.80 | KDR (0.68) | KDRNCF1ADRB2BMPR1BACVRL1 | |
| SCHEMBL5124241 | 0.80 | KDR (0.68) | KDRNCF1ADRB2BMPR1BACVRL1 | |
| Hydrochloric Acid SCHEMBL9128302 | 0.78 | KDR (0.66) | KDRNCF1ADRB2BMPR1BACVRL1 | |
| SCHEMBL4752641 | 0.75 | KDR (0.51) | KDRLATS1MAPTNCF1ADRB2 | |
| SCHEMBL30059061 | 0.73 | KDR (0.59) | KDRNCF1ADRB2DRD2DRD4 | |
| SCHEMBL30059045 | 0.73 | KDR (0.80) | KDRFEN1DRD2DRD4DRD3 | |
| SCHEMBL20128552 | 0.72 | MAPT (0.51) | MAPTNCF1ADRB2PLD1CHRNB2 | |
| SCHEMBL4754853 | 0.72 | KDR (0.54) | KDRMAPTNCF1ADRB2PLD1 | |
| SCHEMBL29498328 | 0.71 | TNKS2 (0.56) | MAPTKDM5AFEN1PARP1PDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1996553-A2 | TUMOR NECROSIS FACTOR ALPHA INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES | Avanir Pharmaceuticals (US) | 2008-12-03 | — | — | EP | disclosed |
| US-20080139551-A1 | TUMOR NECROSIS FACTOR ALPHA INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES | AVANIR PHARMACEUTICALS (US) | 2008-06-12 | — | — | US | disclosed |
| WO-2007109251-A2 | TUMOR NECROSIS FACTOR ALPHA INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES | AVANIR PHARMACEUTICALS (US) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139551-A1 | TUMOR NECROSIS FACTOR ALPHA INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES | TNF, TNFRSF1A, TNFRSF9 | KDR 768/4885LATS1 3630/4885MAPT 2560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.